Notice of Change in RFA-AI-12-020, "Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (R21/R33)," to clarify the "Specific Areas of Research Interest" section of the FOA


Notice Number: NOT-AI-12-030

Key Dates

Release Date:  May 1, 2012

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform potential applicants that the NIAID is revising RFA-AI-12-020, “Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (R21/R33),” to clarify the “Specific Areas of Research Interest” section of the FOA.

The following modification to this FOA is being made:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Specific Areas of Research Interest

CURRENT LANGUAGE:

This initiative seeks to stimulate basic and early-stage translational research focused on development of novel intervention strategies to clear persistent, chronic or latent infectious agents from the host. Responsive applications will define and address a therapeutic need specific to a targeted pathogen.

Examples of possible intervention strategies include, but are not limited to:

Responsive applications must address discovery and/or development of new interventions against one or more agents where the clinical relevance of persistent, chronic and/or latent infection or reactivation there from, in immune-competent hosts is well-established in the scientific literature. 

NEW LANGUAGE:

Specific Areas of Research Interest

This initiative seeks to stimulate basic and early-stage translational research focused on development of novel or enhanced intervention strategies that target established persistent, chronic or latent infections.  Ideally, these strategies will seek to clear the infectious agent(s) from the host, but other approaches that seek to completely and permanently suppress the agent’s pathogenic processes and that do not involve the use of ongoing interventions, will also be considered. Responsive applications will define and address a therapeutic need specific to a targeted pathogen.

Examples of possible intervention strategies include, but are not limited to:

Responsive applications must address discovery and/or development of new or enhanced interventions against one or more agents where the clinical relevance of persistent, chronic and/or latent infection, or reactivation there from, in immune-competent hosts is well-established in the scientific literature. 

All other aspects of the FOA remain unchanged and applicants must meet all requirements of RFA-AI-12-020.

Inquiries

Please direct all inquiries to:

Christopher Beisel, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Division of Microbiology and Infectious Diseases
6610 Rockledge Dr., Room 5145
Bethesda, MD 20892
Telephone: 301-496-7453
Email: cbeisel@niaid.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH . . . Turning Discovery Into Health

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.